In this study, using a BCL-XL-specific inhibitor, A-1331852,23 we demonstrate for the first time, an effective therapeutic option for CML patients with high CIP2A expression levels. The gene discussed is BCL2L1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.